Streetbeat News

PBLA

Panbela Therapeutics Inc.

http://www.sunbiopharma.com/

CEO

Michael Cullen

Open

0.32

Mkt cap

1.6M

Volume

6.3K

High

0.33

P/E Ratio

N/A

52-wk high

38.00

Low

0.32

Div yield

N/A

52-wk low

0.30

In Friday's pre-market session, several healthcare stocks experienced significant movements. Inspire Veterinary (IVP) saw a 178.9% increase, Aclarion (ACON) rose by 115.01%, and Panbela Therapeutics (PBLA) went up by 61.23%. Conversely, Onconetix (ONCO) dropped by 32.8%, Jin Medical International (ZJYL) fell by 18.52%, and Passage Bio (PASG) declined by 11.09%. Other notable movements included gains for Corbus Pharmaceuticals (CRBP), NeuBase Therapeutics (NBSE), and Ainos (AIMD), and losses for PTC Therapeutics (PTCT), Aravive (ARAV), and Sagimet Biosciences (SGMT).

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 1:06 pm

Panbela Therapeutics (NYSE:PBLA) has seen a significant increase in short interest, with the short percent of float rising 912.95% to 14.08% of available shares. It would take about 1.0 days to cover all short positions. While high short interest can indicate bearish sentiment, it doesn't necessarily predict a price drop. Panbela's short interest is higher than its peer group average of 4.23%.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 5:15 pm

During Tuesday's intraday session, several healthcare stocks experienced significant movements. Ensysce Biosciences (ENSC) led the gainers with a 46.5% increase, while Nutex Health (NUTX) saw the largest decline among the losers, dropping 25.6%. Other notable movers included Turnstone Biologics (TSBX), Sensus Healthcare (SRTS), and Outlook Therapeutics (OTLK) with substantial gains, and Atreca (BCEL), Gyre Therapeutics (GYRE), and Aclarion (ACON) with notable losses.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 5:31 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. Ensysce Biosciences (ENSC), Outlook Therapeutics (OTLK), INVO Bioscience (INVO), Kronos Bio (KRON), vTv Therapeutics (VTVT), and Pluri (PLUR) saw their shares rise by 11.03% to 28.1%. Conversely, Inovio Pharmaceuticals (INO), Venus Concept (VERO), Panbela Therapeutics (PBLA), Aclarion (ACON), Renalytix (RNLX), and Aravive (ARAV) witnessed declines ranging from 11.76% to 20.5%.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 1:06 pm

Panbela Therapeutics' stock is trading lower following the announcement of clinical data from CPP-1X studies in neuroblastoma and the effectuation of a 1-for-20 reverse stock split.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 4:13 pm

Trading for PBLA was halted and then resumed at 8:55 AM ET, with updated quotation resumption times following the release of news.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 1:55 pm

Panbela Therapeutics Inc. has announced the publication of a clinical study of DFMO, an investigational drug for cancer treatment, in the British Journal of Cancer. The study's findings support the potential of DFMO as a therapeutic option for patients with pancreatic cancer. This publication could positively influence the perception of Panbela's research and development efforts in the oncology field.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 1:16 pm

Trading on PBLA has been halted at 7:50:00 p.m. ET due to pending news. The halt is in place to manage market orderliness and investor protection pending the release of material information.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 12:50 am

Panbela Therapeutics' stock price is trading lower following the announcement of a 1-for-20 reverse stock split. This corporate action often indicates an attempt to boost the share price to meet exchange listing requirements or to attract new investors by reducing the number of shares outstanding, which can sometimes be perceived negatively by the market.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 6:21 pm

Panbela Therapeutics, Inc. (NASDAQ:PBLA) has announced a 1-for-20 reverse stock split effective January 18, 2024, to increase its stock price and regain compliance with Nasdaq Capital Market listing requirements. The reverse split will reduce the outstanding shares to approximately 480 thousand, with adjustments to warrants, options, and equity incentive plans. The authorized shares for issuance will remain unchanged.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:21 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.